HEALTH OF WOMAN. 2019.10(146): 26–34

xTorshin I. Yu. , Gromova O. A., Limanova O. A.
Russian Center for the Institute of Microelements of UNESCO, Moscow
Ivanovo State Medical Academy
Difficult patient, No. 1-2, V. 13, 2015.

Extracts of Vitex Agnus-castus are used to regulate the menstrual cycle, in the treatment of premenstrual tension syndrome, hyperprolactinemia, and infertility. Vitex extracts component analysis showed the presence of such compounds as vitexin, rotundifuran, kastitsin, artemetin and some phytoestrogens. Extracts compo­nents are characterized with antiinflammatory, antiproliferative, antioxidant, antimicrobial (particularly antifungal), vasoprotective and analgesic effects. The role of the extracts components in modulation of opioid and dopamine receptors has been described. The paper also reviews estrogen modulating and anti-hyperprolactinemic properties of Vitex extracts.
Key words: Vitex Agnus-castus, standardized ex­tracts, phytoestrogens, dopamine receptors modulation, hyperprolactinemia reduction.

REFERENCES

1. Vitex agnus-castus. Monograph. Altern Med Rev. 14 (1): 67-71. 2009.

2. Tandon S, Mittal AK, Pant AK. 2008. Insect growth regulatory activity of Vitex trifolia and Vitex agnus-castus essential oils against Spilosoma obli-qua. Fitoterapia 79 (4): 283-6.

3. Sharon R, Soroker V, Wesley SD et al. 2005. Vitex agnus-castus is a pre­ferred host plant for Hyalesthes obsoletus. J Chem Ecol. 31(5): 1051-1063.

4. Rani A, Sharma A. 2013. The genus Vitex: A review. Pharmacogn Rev. 7(14): 188-98.

5. Lataoui M, Seffen M, Aliakbarian B et al. 2014. Optimisation of phenolics recovery from Vitex agnus-castus Linn. leaves by high-pressure and tem-perature extraction. Nat Prod Res. 28 (1): 67-9.

6. Liu QY, Chen YS, Wang F et al. 2014. Chemical of Vitex trifolia. Zhongguo Zhong Yao Za Zhi. 39 (11): 2024-2028.

7. Sena Filho JG, Duringer J, Maia GL et al. 2008. Ecdysteroids from Vitex species: distribution and compilation of their 13C-NMR spectral data. Chem Biodivers. 5(5): 707-13.

8. Hogner C, Sturm S, Seger C, Stuppner H. 2013. Development and valida­tion of a rapid ultra-high performance liquid chromatography diode array detector method for Vitex agnus-castus. J Chromatogr B Analyt Technol Biomed Life Sci. 927: 181-90.

9. Mari A, Montoro P, D’Urso G et al. 2014, Dec. Metabolic profiling of Vitex agnus- castus leaves, fruits and sprouts: Analysis by LC/ESI/(QqQ)MS and (HR) LC/ESI/(Orbitrap)/MS J Pharm Biomed Anal. 102C: 215­221. 31(12):1564-8.

10. Kuruuzum-Uz A, Stroch K, Demirezer LO, Zeeck A. 2003. Glucosides from Vitex agnus-castus. Phytochemistry 63 (8): 959-964.

11. Ono M, Yamasaki T, Konoshita M et al. 2008. Five new diterpenoids, vite- agnusins A-E, from the fruit of Vitex agnus-castus. Chem Pharm Bull (To-kyo). 56(11): 1621-1624.

12. Hirobe C, Qiao ZS, Takeya K, Itokawa H. 1997. Cytotoxic flavonoids from Vitex agnus-castus. Phytochemistry 46(3): 521-524.

13. Li S, Qiu S, Yao P et al. 2013. Compounds from the Fruits of the Popular European Medicinal Plant Vitex agnus-castus in Chemoprevention via NADP(H):Quinone Oxidoreductase Type 1 Induction. Evid Based Comple-ment Alternat Med. 2013: 432829.

14. Marongiu B, Piras A, Porcedda S et al. 2010. Extraction, separation and isolation of volatiles from Vitex agnus-castus L. (Verbenaceae) wild speci-es of Sardinia, Italy, by supercritical CO2. Nat Prod Res. 24 (6): 569-79.

15. Ghannadi A, Bagherinejad M, Abedi D et al. 2012. Antibacterial activity and composition of essential oils from Pelargonium graveolens L’Her and Vitex agnus-castus L. Iran J Microbiol. 4 (4): 171-176.

16. Sorensen JM, Katsiotis ST. 2000. Parameters influencing the yield and composition of the essential oil from Cretan Vitex agnus-castus fruits. Planta Med. 66 (3): 245-250.

17. Pan JG, Xu ZL, Fan JF. 1989. GC-MS analysis of essential oils from four Vitex species. Zhongguo Zhong Yao Za Zhi. 14(6): 357-9, 383.

18. Wollenweber E, Mann K. 1983. Flavonols from Fruits of Vitex agnus-ca­stus. Planta Med. 48 (2): 126-127.

19. Sirait M, Rimpler H, Haensel R. 1962. Flavonoids from Vitex agnus-castus L. Experientia. 18: 72.

20. Li MM, Su XQ, Sun J et al. 2014. Anti-inflammatory Ursane – and Ole- anane-Type Triterpenoids from Vitex negundo var. cannabifolia. J Nat Prod. 77 (10): 2248-54.

21. Tiwari N, Thakur J, Saikia D, Gupta MM. 2013.Antitubercular diterpenoids from Vitex trifolia. Phytomedicine. 20(7): 605-10.

22. Rudrapaul P, Sarma IS, Das N et al. 2014. New flavonol methyl ether from the leaves of Vitex peduncularis exhibits potential inhibitory activity against Leishmania donovani through activation of iNOS expression. Eur J Med Chem. 87C: 328-335.

23. Kamruzzaman M, Bari SM, Faruque SM. 2013. In vitro and in vivo bacte­ricidal activity of Vitex negundo leaf extract against diverse multidrug resi­stant enteric bacterial pathogens. Asian Pac J Trop Med. 6 (5): 352-9.

24. Jarry H, Spengler B, Porzel A et al. 2003. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med. 69 (10): 945-947.

25. Ibrahim NA, Shalaby AS, Farag RS Et al. 2008. Gynecological efficacy and chemical investigation of Vitex agnus-castus L. fruits growing in Egypt. Nat Prod Res. 22(6): 537-46.

26. Hu Y, Hou TT, Zhang QY et al. 2007. Evaluation of the estrogenic activity of the constituents in the fruits of Vitex rotundifolia L. for the potential trea­tment of premenstrual syndrome. J Pharm Pharmacol. 59(9): 1307-1312.

27. Liu J, Burdette JE, Xu H, Gu C et al. 2001. Evaluation of estrogenic acti­vity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 49 (5): 2472-2479.

28. Van Die MD, Burger HG, Teede HJ, Bone KM. 2013. Vitex agnus-ca­stus extracts for female reproductive disorders: a systematic review of cli­nical trials. Planta Med. 79 (7): 562-75.

29. Blumenthal M. 2003. The ABC Clinical Guide to Herbs. New York, NY, Thie- me: 61-72.

30. Carmichael AR. 2008. Can Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence? Evid Based Complement Al­ternat Med. 5 (3): 247-50.

31. Hu Y, Xin HL, Zhang QY et al. 2007. Anti-nociceptive and anti-hyperpro­lactinemia activities of Fructus Viticis and its effective fractions and chemi­cal constituents. Phytomedicine 14(10): 668-74. Epub 2007 Ma.

32. Ye Q, Zhang QY, Zheng CJ et al. 2010. Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro. Acta Phar­macol Sin.

33. Azarnia M, Ejtemaei-Mehr S, Shakoor A, Ansari A. 2007. Effects of Vitex agnus-castus on mice fetus Development. Acta Med Iran. 45: 264-70.

34. Park SE, Sapkota K, Choi JH et al. 2014. Rutin from Dendropanax mor- bifera Leveille protects human dopaminergic cells against rotenone indu­ced cell injury through inhibiting JNK and p38 MAPK signaling. Neurochem Res. 39 (4): 707-18.

35. Shen W, Qi R, Zhang J et al. 2012. Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons. Brain Res Bull. 88 (5): 487-94.

36. Chen HQ, Jin ZY, Wang XJ et al. 2008. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett. 448 (2): 175-9.

37. Wang J, Xu H, Jiang H et al. 2012. Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson’s disease. J Mol Neurosci. 47 (1): 113-9.

38. Meier B, Berger D, Hoberg E et al. 2000. Pharmacological activities of Vi­tex agnus-castus extracts in vitro. Phytomedicine 7(5): 373-381.

39. Nasri S, Oryan S, Rohani AH, Amin GR. 2007. The effects of Vitex ag­nus-castus extract and its interaction with dopaminergic system on LH and testosterone in male mice. Pak J Biol Sci. 10(14): 2300-2307.

40. Webster DE, Lu J, Chen SN et al. 2006. Activation of the mu-opiate re­ceptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J Ethnopharmacol. 106 (2): 216-21. Epub 2006 Ja.

41. Dhawan BN, Cesselin F, Raghubir R et al. 1996. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 48 (4): 567-592.

42. Janecka A, Fichna J, Janecki T. 2004. Opioid receptors and their ligands. Curr Top Med Chem. 4 (1): 1-17.

43. Webster DE, He Y, Chen SN et al. 2011. Opioidergic mechanisms un­derlying the actions of Vitex agnus-castus L. Biochem Pharmacol. 81(1): 170-7.

44. Katzung B. 2007. Basic & clinical pharmacology. 10th edition. McGraw-Hill Medical: 489-490:1200: ISBN 0071604057.

45. Demir Ozkay U, Can OD. 2013. Anti-nociceptive effect of vitexin mediated by the opioid system in mice. Pharmacol Biochem Behav. 109: 23-30.

46. Chen SN, Friesen JB, Webster D et al. 2011. Phytoconstituents from Vi­tex agnus-castus fruits. Fitoterapia 82 (4): 528-33.

47. Katsuyama S, Mizoguchi H, Kuwahata H et al. 2013. Involvement of peri­pheral cannabinoid and opioid receptors in beta-caryophyllene-induced antinociception. Eur J Pain. 17(5): 664-75.

48. Макарова МН, Макаров ВГ. 2010. Молекулярная биология флаво- ноидов. СПб, Лема: 438.

49. Sohn SH, Ko E, Oh BG et al. 2009. Inhibition effects of Vitex rotundifolia on inflammatory gene expression in A549 human epithelial cells. Ann Aller­gy Asthma Immunol. 103(2): 152-9.

50. Bae H, Kim Y, Lee E et al. 2013. Vitex rotundifolia L. prevented airway eo­sinophilic inflammation and airway remodeling in an ovalbumin-induced asthma mouse model. Int Immunol. 25 (3): 197-205.

51. Chattopadhyay P, Hazarika S., Dhiman S et al. 2012. Vitex negundo inhi­bits cyclooxygenase-2 inflammatory cytokine-mediated inflammation on carrageenan-induced rat hind paw edema. Pharmacognosy Res. 4 (3): 134-7.

52. Zheng CJ, Zhao XX, Ai HW et al. 2014. Therapeutic effects of standardi­zed Vitex negundo seeds extract on complete Freund’s adjuvant induced arthritis in rats. Phytomedicine 21(6): 838-46.

53. Choudhary MI, Jalil S, Nawaz SA et al. 2009. Antiinflammatory and lipo­xygenase inhibitory compounds from Vitex agnus-castus. Phytother Res. 23(9): 1336-9.

54. Mesaik MA, Murad S, Khan KM et al. 2009. Isolation and immunomo­dulatory properties of a flavonoid, casticin from Vitex agnus-castus. Phy- tother Res. 23(11): 1516-20.

55. Kikuchi H, Yuan B, Yuhara E et al. 2014. Involvement of histone H3 phosp­horylation via the activation of p38 MAPK pathway and intracellular redox status in cytotoxicity of HL-60 cells induced by Vitex agnus-castus fruit ex­tract. Int J Oncol. 45 (2): 843-52.

56. Weisskopf M, Schaffner W, Jundt G et al. 2005. A Vitex agnus-castus ex­tract inhibits cell growth and induces apoptosis in prostate epithelial cell li­nes. Planta Med. 71(10): 910-916.

57. Ohyama K, Akaike T, Hirobe C, Yamakawa T. 2003. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull. 26 (1): 10-18.

58. Ohyama K, Akaike T, Imai M et al. 2005. Human gastric signet ring carci­noma (KATO-III) cell apoptosis induced by Vitex agnus-castus fruit extract through intracellular oxidative stress. Int J Biochem Cell Biol. 37(7): 1496-1510.

59. Kikuchi H, Yuan B, Nishimura Y et al. 2013. Cytotoxicity of Vitex agnus-ca- stus fruit extract and its major component, casticin, correlates with diffe­rentiation status in leukemia cell lines. Int J Oncol. 43(6): 1976-84.

60. Qu L, Liu FX, Cao XC et al. 2014. Activation of the apoptosis signal-regu­lating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin- induced apoptosis of colon cancer cells. Exp Ther Med. 8 (5): 1494-1500. Epub 2014.

61. Haidara K, Zamir L, Shi QW, Batist G. 2006. The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett. 242 (2): 180-90. Epub 2006 Ja.

62. Wang J, Zheng X, Zeng G et al. 2014. Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma. Int J Mol Med. 33 (2): 441-8.

63. Zhou J, Hu H, Long J et al. 2013. Vitexin 6, a novel lignan, induces auto- phagy and apoptosis by activating the Jun N-terminal kinase pathway. An­ticancer Drugs. 24 (9): 928-36.

64. Long X, Fan M, Bigsby RM, Nephew KP. 2008. Apigenin inhibits anti­estrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mecha­nisms. Mol Cancer Ther. 7(7): 2096-108.